OBJECTIVES: A significant proportion of patients with major depressive disorder (MDD) do not improve following treatment with first-line antidepressants and, currently, there are no objective indicators of predictors of antidepressant response. The aim of this study was to investigate pre-treatment peripheral gene expression differences between future remitters and non-responders to citalopram treatment and identify potential pharmacogenomic predictors of response. METHODS: We conducted a gene expression study using Affymetrix HG-U133 Plus2 microarrays in peripheral blood samples from untreated individuals with MDD (N = 77), ascertained at a community outpatient clinic, prior to an 8-week treatment with citalopram. Gene expression differences were assessed between remitters and non-responders to treatment. Technical validation of significant probesets was carried out by qRT-PCR. RESULTS: A total of 434 probesets displayed significant correlation to change in score and 33 probesests were differentially expressed between eventual remitters and non-responders. Probesets for SMAD 7 (SMA- and MAD-related protein 7) and SIGLECP3 (sialic acid-binding immunoglobulin-like lectin, pseudogene 3) were the most significant differentially expressed genes following FDR correction, and both were down-regulated in individuals who responded to treatment. CONCLUSIONS: These findings point to SMAD7 and SIGLECP3 as candidate predictive biomarkers of antidepressant response.
OBJECTIVES: A significant proportion of patients with major depressive disorder (MDD) do not improve following treatment with first-line antidepressants and, currently, there are no objective indicators of predictors of antidepressant response. The aim of this study was to investigate pre-treatment peripheral gene expression differences between future remitters and non-responders to citalopram treatment and identify potential pharmacogenomic predictors of response. METHODS: We conducted a gene expression study using Affymetrix HG-U133 Plus2 microarrays in peripheral blood samples from untreated individuals with MDD (N = 77), ascertained at a community outpatient clinic, prior to an 8-week treatment with citalopram. Gene expression differences were assessed between remitters and non-responders to treatment. Technical validation of significant probesets was carried out by qRT-PCR. RESULTS: A total of 434 probesets displayed significant correlation to change in score and 33 probesests were differentially expressed between eventual remitters and non-responders. Probesets for SMAD 7 (SMA- and MAD-related protein 7) and SIGLECP3 (sialic acid-binding immunoglobulin-like lectin, pseudogene 3) were the most significant differentially expressed genes following FDR correction, and both were down-regulated in individuals who responded to treatment. CONCLUSIONS: These findings point to SMAD7 and SIGLECP3 as candidate predictive biomarkers of antidepressant response.
Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112
Authors: Michelle M Kittleson; Khalid M Minhas; Rafael A Irizarry; Shui Q Ye; Gina Edness; Elayne Breton; John V Conte; Gordon Tomaselli; Joe G N Garcia; Joshua M Hare Journal: Int J Cardiol Date: 2005-07-10 Impact factor: 4.164
Authors: Brandi Rollins; Maureen V Martin; Ling Morgan; Marquis P Vawter Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-06-05 Impact factor: 3.568
Authors: Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris Journal: JAMA Date: 2008-01-30 Impact factor: 56.272
Authors: Annamaria Cattaneo; Massimo Gennarelli; Rudolf Uher; Gerome Breen; Anne Farmer; Katherine J Aitchison; Ian W Craig; Christoph Anacker; Patricia A Zunsztain; Peter McGuffin; Carmine M Pariante Journal: Neuropsychopharmacology Date: 2012-09-19 Impact factor: 7.853
Authors: Harris A Eyre; Ascia Eskin; Stanley F Nelson; Natalie M St Cyr; Prabha Siddarth; Bernhard T Baune; Helen Lavretsky Journal: Int J Geriatr Psychiatry Date: 2015-10-15 Impact factor: 3.485
Authors: J M Hennings; M Uhr; T Klengel; P Weber; B Pütz; C Touma; D Czamara; M Ising; F Holsboer; S Lucae Journal: Transl Psychiatry Date: 2015-03-31 Impact factor: 6.222
Authors: Anne Skøttrup Mørkholt; Ove Wiborg; Jette G K Nieland; Søren Nielsen; John Dirk Nieland Journal: Sci Rep Date: 2017-05-19 Impact factor: 4.379
Authors: Ian A Cook; Eliza Congdon; David E Krantz; Aimee M Hunter; Giovanni Coppola; Steven P Hamilton; Andrew F Leuchter Journal: Front Genet Date: 2019-09-18 Impact factor: 4.599